5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 4.92▼ | 4.94▼ | 4.95▼ | 4.97▲ | 5.18▼ |
MA10 | 4.95▼ | 4.99▼ | 4.92▼ | 4.98▲ | 6.64▼ |
MA20 | 4.96▼ | 4.99▼ | 5.05▼ | 5.09▼ | 6.85▼ |
MA50 | 5.09▼ | 5.14▼ | 5.05▼ | 6.72▼ | 5.84▼ |
MA100 | 5.16▼ | 5.07▼ | 5.17▼ | 6.68▼ | N/A |
MA200 | 5.06▼ | 5.71▼ | 6.44▼ | 5.67▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▼ | -0.003▼ | -0.010▼ | 0.096▲ | -0.409▼ |
RSI | 42.807▼ | 43.569▼ | 43.923▼ | 39.174▼ | 41.118▼ |
STOCH | 4.768▼ | 14.866▼ | 30.401 | 29.165 | 12.839▼ |
WILL %R | -97.561▼ | -81.633▼ | -71.429 | -64.957 | -92.208▼ |
CCI | -68.682 | -49.194 | -35.569 | -6.189 | -105.247▼ |
Wednesday, April 16, 2025 03:05 PM
The grant to Dr. Shah provides for the issuance of 191,624 stock options. Additionally, the grants to the two employees provide for the issuance of an aggregate of 21,000 stock options. Each grant ...
|
Wednesday, April 16, 2025 09:05 AM
Elicio Therapeutics Inc. BOSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company ...
|
Tuesday, April 15, 2025 09:16 PM
Inc. (Nasdaq: ELTX,“Elicio Therapeutics” or“Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/05/25 | 5.02 | 5.15 | 4.89 | 5.02 | 27,125 |
30/04/25 | 4.94 | 4.94 | 4.86 | 4.92 | 11,349 |
29/04/25 | 4.97 | 4.97 | 4.75 | 4.82 | 12,834 |
28/04/25 | 5.255 | 5.29 | 4.85 | 4.97 | 27,893 |
25/04/25 | 5.25 | 5.78 | 5.03 | 5.13 | 37,920 |
24/04/25 | 5.25 | 5.60 | 5.00 | 5.07 | 116,463 |
23/04/25 | 5.23 | 5.68 | 5.105 | 5.22 | 103,972 |
22/04/25 | 4.98 | 5.3565 | 4.93 | 5.05 | 15,288 |
21/04/25 | 4.83 | 4.98 | 4.695 | 4.80 | 34,093 |
17/04/25 | 4.94 | 5.10 | 4.76 | 4.76 | 16,039 |
|
|
||||
|
|
||||
|
|